Migration of Cultured Chimpanzee Dendritic Cells Following Intravenous and Subcutaneous Injection

  • Simon M. Barratt-Boyes
  • Simon C. Watkins
  • Olivera J. Finn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 417)


In recent years much interest has been generated in using dendritic cells as vehicles for cancer immunotherapy1. This interest is based on the fact that dendritic cells function as specialized immunostimulatory cells in vivo, serving as initiators of T cell immune responses to antigen2. The dendritic cell-based approach to immunotherapy is feasible because of two advances: the identification and isolation of specific human tumor-associated antigens, and the development of techniques to propagate dendritic cells in vitro from precursor cells3,4. Hence, it is now possible to grow large numbers of dendritic cells from a patient’s blood or bone marrow in vitro, treat these cells with tumor-associated antigens, and administer to the donor with the aim of inducing a strong and therapeutic immune response to the tumor. The therapeutic efficacy of the technique has been tested in murine tumor models5, and clinical trials in cancer patients are being initiated6.


Dendritic Cell Drain Lymph Node Inguinal Lymph Node Immunotherapy Protocol Yerkes Regional Primate Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grabbe S, Biessert S, Schwarz T, Granstein RD (1995). Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16, 117–121.PubMedCrossRefGoogle Scholar
  2. 2.
    Steinman RM (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9, 271–296.PubMedCrossRefGoogle Scholar
  3. 3.
    Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992). GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261.PubMedCrossRefGoogle Scholar
  4. 4.
    Sallusto F, Lanzavecchia A (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor a. J Exp Med 179, 1109–11 18.Google Scholar
  5. 5.
    Mayordomo Jl, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, DeLco AB, Lotze ML (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1, 1297–1302.CrossRefGoogle Scholar
  6. 6.
    Hsu FJ, Bcnike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2, 52–58.PubMedCrossRefGoogle Scholar
  7. 7.
    Austyn JM, Larsen CP (1990). Migration patterns of dendritic leukocytes. Transplantation 49, 1–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Macatonia SE, Edwards AJ, Knight SC (1986). Dendritic cells and contact sensitivity to fluorescein isothiocyanate. Immunology 59, 509–514.PubMedGoogle Scholar
  9. 9.
    Fossum S (1988). Lymph-borne dendritic leukocytes do not recirculate, but enter the lymph node para-cortex to become interdigitating cells. Scand J Immunol 27, 97–105.PubMedCrossRefGoogle Scholar
  10. 10.
    Kupiec-Weglinski JW, Austyn JM, Morris PJ (1988). Migration patterns of dendritic cells in the mouse: Traffic from the blood, and T cell-dependent and independent entry to lymphoid tissues. J Exp Med 167, 632–645.Google Scholar
  11. 11.
    Barratt-Boyes SM, Henderson RA, Finn OJ (1996). Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood. Immunology 87, 528–534.PubMedCrossRefGoogle Scholar
  12. 12.
    Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM (1995). Dendritic cell loss from non-lymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1.1 Exp Med 181, 2237–2247.Google Scholar
  13. 13.
    Mai, Wang J-H, Guo Y-J, Sy M-S, Bigby M (1994). In vivo treatment with anti-ICAM-1 and anti-LFA-1 antibodies inhibits contact sensitization-induced migration of epidermal Langerhans cells to regional lymph nodes. Cell Immunol 158, 389–399.CrossRefGoogle Scholar
  14. 14.
    Henderson RA, Nimgoankar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ (1996). Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56, 3763–3770.PubMedGoogle Scholar
  15. 15.
    Austyn JM, Kupiec-Weglinski JW, Hankins DE, Morris PJ (1988). Migration patterns of dendritic cells in the mouse: Homing to T cell-dependent areas of spleen, and binding within marginal zone. 1 Exp Med 167, 646–651.Google Scholar
  16. 16.
    Morikawa Y, Furotani M, Kuribayashi K, Matsuura N, Kakudo K (1992). The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells. Immunology 77, 81–87.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Simon M. Barratt-Boyes
    • 1
  • Simon C. Watkins
    • 2
  • Olivera J. Finn
    • 1
    • 3
  1. 1.Department of Molecular Genetics and BiochemistryUniversity of PittsburghPittsburghUSA
  2. 2.Department of Cell Biology and PhysiologyUniversity of PittsburghPittsburghUSA
  3. 3.Yerkes Regional Primate Research CenterEmory UniversityAtlantaGeorgia

Personalised recommendations